Thu, Oct 2, 2014, 3:22 AM EDT - U.S. Markets open in 6 hrs 8 mins

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

smelky_kid 373 posts  |  Last Activity: Sep 29, 2014 2:29 PM Member since: Jun 9, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • smelky_kid by smelky_kid Sep 29, 2014 2:29 PM Flag

    That's all you can do. Today's market is filled with the same trading pool, moving from one sector to another, and always looking for a reason to take a profit and scare people along the way...

  • smelky_kid by smelky_kid Sep 17, 2014 3:18 PM Flag

    Clearly, revenue prospects must be falling. Management has no interest in shareholder value. They had us vote in favor of a reverse split to gain exposure and now have done nothing to benefit shareholders by keeping us off any Nasdaq listing . The company management is in a tailspin. We are hurdling back to the 20's people...See you all down there....

  • Reply to

    Another service deal with GSK

    by smelky_kid Sep 12, 2014 10:19 AM
    smelky_kid smelky_kid Sep 12, 2014 1:28 PM Flag

    All I do is speculate. Despite what you say about the prospects here, DDXS is in the process of heading back to its all time low. Revenues are growing, the sales force is growing, and the stock is now trading at only 1 times sales. So, the confidence you perceive by the company is reflected as the exact opposite by investors...
    Of course it is in Glaxo's best interest to keep DDXS stable, however, what does that say about our interests. If management had a lucrative buyout offer, how do you know that Glaxo is not threatening to withdraw the intellectual property? And if that is the case, then Glaxo's interests here are not in the best interest of shareholders. I am here to make money, not watch Glaxo squash a company so that their test data is kept safe and secure....

  • Surely, Glaxo has some endeavure to resurrect Darapladib. It seems that GSK is paying Diadexus for laboratory work in relation to the 30,000 patients blood work, searching for that elusive subset of patients that had some statistical success after taking the drug. The service agreement was originally pegged at 3 million dollars and has now been increased to 4.8 million. This should clearly help Diadexus revenues, although these are one-time sources of funds. DDXS needs to show a profit this quarter, they need to do a reverse split, and they need to sell the company. It's possible Glaxo, with their ownership of DDXS, has forbidden management from selling the company, because of confidentiality reasons related to this service agreement. Perhaps that is the reason that the CFO has resigned. Glaxo pulls the strings with this company. At any moment, Glaxo can take back the intellectual property related to LP-PLA2 and end the company's only source of revenue. That is my bet. DDXS has lost control of its future....

  • Lost the CEO, CFO just resigned... The dream is over for Diadexus. Maybe they can get 1 dollar in a sale...

  • Reply to

    Slug, wow.

    by smelky_kid Aug 28, 2014 10:19 AM
    smelky_kid smelky_kid Sep 8, 2014 1:19 PM Flag

    I was referring to CONX... unreal.

  • smelky_kid by smelky_kid Aug 28, 2014 10:49 AM Flag

    Rough market.

  • Sorry....

  • smelky_kid by smelky_kid Aug 28, 2014 10:19 AM Flag

    I feel for you.

  • 15 million dollar market cap company... Makes no sense, but this was the case a couple of years ago. Look for a new re-entry price of about 25 or 30 cents. Should get there by Jan 1. I really don't think management has any interest in promoting the price of the stock... They were lethargic on the way up and they are equally lethargic on the way down...With the binary event of Darapladib gone, no one really has any zeal for this type of company. This will be a slow bleed into the 30's. And if the reverse split does not take place by the end of the summer, then you really have a super-lethargic company that wants to see this round-trip back into the 20s or even lower.

  • I think they were waiting to complete today's bank debt refinancing... With that out of the way, I think the reverse comes ASAP.

  • because the data was too good. too good. "by not stopping the trial early, we are putting the placebo patients in grave danger." Every single date the company or analysts use as the expected time for the drug to receive FDA approval is incorrect. The staggering good data will force the hand of the FDA. Look for an expidited review, with post-approval monitoring. The data is just too good. The amount of brand new revenue streams coming out of drug research is amazingly low. Intercept is at the precipice of a new revenue stream that can approach 5 billion dollars per year(within 6 years). There is not one pharmaceutical company in the world that will not engage in merger talks to get their hands on this cash flow. Not a one. ICPT is a 4 digit stocks, eventually.

  • or 1500 in 2 years.

  • Will keep a small piece for posterity but the time has come to find some new opportunities.
    Good luck everyone.

  • smelky_kid by smelky_kid Jul 30, 2014 2:48 PM Flag

    With revenues up 23% to 7.8 million, and a loss of $400 thousand dollars, this company had better cut some of the jelly and start showing a profit. Teetering on the edge of profitability with 7.8 million coming in seems pretty pathetic at this point. With the stock in a steady downtrend, management needs to turn this around with steady profits. We are now projected to generate 30 million in revenues, and are trading with a 38 million dollar market cap. Something is amiss. Either, no one wants to correct the situation, which I believe comes from a lack of visibility due to the sub 1 dollar stock price(which is why I believe a 1 for 5 reverse split is needed) or someone knows something about PLAC sales plummeting for some reason in the future(which I doubt). So lets split the shares and get some people to notice how low the market cap is....

  • Reply to

    Secondary analysis

    by sschatzi33 Jun 23, 2014 2:58 PM
    smelky_kid smelky_kid Jul 2, 2014 12:06 PM Flag

    Cobb, I haven't lost faith in ddxs. In fact, I own the most shares I've ever held. I don't hold for Dara, I hold for continued usage of Plac test.
    I haven't lost any faith in making serious money here....

  • Reply to

    Secondary analysis

    by sschatzi33 Jun 23, 2014 2:58 PM
    smelky_kid smelky_kid Jul 2, 2014 10:50 AM Flag

    Come on guys, lets be realistic. The worst mistake in investing is clinging to some shred of hope that we all know no longer exists. Darapladib is done. It's possible that Rilapladib has a chance, and that is why Glaxo bought the 3 million in Plac tests. Don't waste your brain cells on Darapladib. It was a long shot for us and I imagine it was the reason Brian Ward stuck around. Now we know why he left...We can still make money here but the great Darapladib gap up just ain't gonna happen.
    As always, keepin' it real....

  • Reply to

    What happened on June 4rth?

    by jwilbanks Jun 7, 2014 9:23 AM
    smelky_kid smelky_kid Jun 9, 2014 4:07 PM Flag

    Well I am hoping you are right, this time! touche.

  • Reply to

    What happened on June 4rth?

    by jwilbanks Jun 7, 2014 9:23 AM
    smelky_kid smelky_kid Jun 9, 2014 9:35 AM Flag

    Thanks sir. In your opinion, what sort of biomarker analysis could there be that has a real value to Diadexus?

  • Reply to

    What happened on June 4rth?

    by jwilbanks Jun 7, 2014 9:23 AM
    smelky_kid smelky_kid Jun 8, 2014 9:14 PM Flag

    So what are you trying to say here? You have a bunch of cryptic sentences in your last 2 posts. I've read these posts 5 times each and clearly you have some insight into the ct filing and some unreleased biomarker analysis. Spit it out in English, please.... It's hard enuf scrolling thru this penny stock scammer, and then your mystery stufffffffffff

SGEN
36.92-0.26(-0.70%)Oct 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.